Indian Journal of Urology Users online:3247  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size
This article has been cited by
1Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events
F. Hall,H. M. de Freitas,C. Kerr,T. Ito,B. Nafees,A. J. Lloyd,J. Penton,M. Hadi,S. Lanar,T. P. Pham
Quality of Life Research.2019;28(5)1191
[DOI]
2Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
S. V. Popov
Medical Council.2019;28(19)170
[DOI]
3Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries
Hayley M. de Freitas,Tetsuro Ito,Monica Hadi,Gemma Al-Jassar,MickaŽl Henry-Szatkowski,Beenish Nafees,Andrew J. Lloyd
Advances in Therapy.2019;36(2)318
[DOI]
4HCRP1 regulates proliferation, invasion, and drug resistance via EGFR signaling in prostate cancer
Liang Sun,Jiaju LŁ,Sentai Ding,Dongbin Bi,Kejia Ding,Zhihong Niu,Ping Liu
Biomedicine & Pharmacotherapy.2017;91(2)202
[DOI]
  Search 
  The Journal 
  The Association 
  Site Statistics 
  Addresses 
  e-Alerts 
  Online Submission 

Submit Articles

Alerts

Join us

HEALTHWARE INDIA